Evidence map›Paper›PMID 36106611›Full record

Trial reportClinical and translational science2022

The ATEAM study: Advances in technology to enhance PrEP adherence monitoring (ATEAM) among young men who have sex with men.

Jennifer Brothers, Sybil Hosek, Kody Keckler, Peter L Anderson, Di Xiong, Honghu Liu, Gregory Huhn

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Jennifer BrothersHektoen Institute of Medicine, Chicago, Illinois, USA.
Sybil HosekStroger Hospital of Cook County, Chicago, Illinois, USA.
Kody KecklerHektoen Institute of Medicine, Chicago, Illinois, USA.
Peter L AndersonUniversity of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Di XiongDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, California, USA.
Honghu LiuDivision of Oral and Systemic Health Sciences, School of Dentistry, University of California, Los Angeles, California, USA.
Gregory HuhnStroger Hospital of Cook County, Chicago, Illinois, USA.
University of California System · USCook County Department of Public Health · USHektoen Institute · USJohn H. Stroger, Jr. Hospital of Cook County · USRuth M. Rothstein CORE Center · USUniversity of Montana · US

Funding

Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSMR01AI122308 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI HUHN, GREGORY D · 2016 to 2019
$1.8M
NIAID NIH HHS R01 AI122308
6 · The paper itself

Abstract

Young age has consistently correlated with lower adherence to pre-exposure prophylaxis (PrEP) in young men who have sex with men (YMSM). Digital medicine, a dynamic healthcare platform of wearable physiological sensors and mobile communication technology that can respond to medication nonadherence rapidly, has the potential in promoting PrEP adherence. We evaluated the feasibility and acceptability of Proteus Discover, a digital monitoring adherence system, to measure PrEP adherence and provide real-time feedback among cisgender YMSM and transgender women. One hundred HIV-negative young men and transgender women ages 16-24 years were enrolled in a 24-week randomized controlled crossover study to tenofovir disoproxil fumarate with emtricitabine (TDF/FTC) coencapsulated with Proteus Discover versus TDF/FTC standard-of-care. Participants in the 12-week Proteus Discover arm received weekly SMS text messages to promote pill taking based on Proteus Discover adherence data. Dried blood spots (DBS) were collected at 4-week intervals for tenofovir diphosphate (TFV-DP) in red blood cells as the referent and questionnaires were completed to assess acceptability, usability, and patterns of use. Linear mixed models analyzed the relationship between 30-day adherence measured by DBS and Proteus Discover. PrEP adherence was high overall. Adherence, as measured by DBS, was correlated with adherence as measured by Proteus Discover (p value = 0.03). Most participants reported that Proteus Discover helped them take their PrEP daily and that the system was easy to use. However, a majority (53.5%-60.5%) disagreed with the statement that wearing the patch was not an issue. There was an incremental increase in TFV-DP in DBS with adherence by Proteus Discover. More research is warranted to explore optimizing PrEP adherence for youth through real-time monitoring.

Indexed as

Anti-HIV AgentsHIV InfectionsSexual and Gender MinoritiesAdenineAdolescentAdultCross-Over StudiesEmtricitabineFemaleHomosexuality, MaleHumansMaleMedication AdherenceOrganophosphatesTechnologyTenofovirAdenineAnti-HIV AgentsEmtricitabineOrganophosphatesTenofovirtenofovir diphosphate

Identifiers

PMID36106611
PMCPMC9747125
OpenAlexW4295904826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.